Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:NLTX
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- P/E Growth:
Frequently Asked Questions for Capricor Therapeutics (NASDAQ:NLTX)
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include Orange Belgium (MBSRF), Abengoa SA (ABGB), Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft (MSFT), Amazon.com (AMZN), Facebook (FB), Premier Foods Spon (PRRFY), Berkshire Hathaway (BRK-A), Nestle SA (NSRGY), Roche Holding (RHHBY), RDS-A (RDS-A), Comcast (CMCSA), Intel (INTC), Cisco Systems (CSCO), LVMH Moet Hennessy Louis Vuitton SE (LVMUY) and Inditex (IDEXY).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board
- Linda Marban Ph.D., President, Chief Executive Officer, Director
- Leland J. Gershell M.D. Ph.D., Chief Financial Officer, Principal Financial Officer
- Karen G. Krasney J.D., Executive Vice President, General Counsel
- Anthony Bergmann, Principal Accounting Officer, Vice President - Finance
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development
- Deborah Ascheim M.D., Chief Medical Officer
How do I buy Capricor Therapeutics stock?
Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
MarketBeat Community Rating for Capricor Therapeutics (NASDAQ NLTX)MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Capricor Therapeutics stock can currently be purchased for approximately $0.08.
Consensus Ratings for Capricor Therapeutics (NASDAQ:NLTX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Capricor Therapeutics (NASDAQ:NLTX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Capricor Therapeutics (NASDAQ:NLTX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Capricor Therapeutics (NASDAQ:NLTX)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $0.00 EPS
Dividend History for Capricor Therapeutics (NASDAQ:NLTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Capricor Therapeutics (NASDAQ:NLTX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Capricor Therapeutics (NASDAQ:NLTX)
Latest Headlines for Capricor Therapeutics (NASDAQ:NLTX)
No headlines for this company have been tracked by MarketBeat.com
Capricor Therapeutics (NLTX) Chart for Monday, May, 29, 2017